𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

✍ Scribed by O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. Thalamas; A.M. Bonnet; S. Descombes; B. Bejjani; N. Fabre; J.L. Montastruc; Y. Agid

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
246 KB
Volume
16
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia. We assessed, in a pilot randomised placebo‐controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha‐2 antagonist, on motor parkinsonian disability and L‐DOPA‐induced dyskinesia following an acute oral challenge of L‐DOPA in 18 patients with Parkinson's disease. The severity of L‐DOPA‐induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L‐DOPA. These results suggest that blocking alpha‐2 receptors in patients with Parkinson's disease might improve L‐DOPA‐induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long‐term management of dyskinetic patients with Parkinson's disease. © 2001 Movement Disorder Society.

📜 SIMILAR VOLUMES

Simultaneous MAO-B and COMT inhibition i
Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with parkinson's disease
✍ Dr. Jukka Lyytinen; Seppo Kaakkola; Sirpa Ahtila; Päivi Tuomainen; Heikki Terävä 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 801 KB

## Abstract The effect of selegiline (L‐deprenyl) on plasma catecholamines, clinical response, and drug tolerability was studied in 13 patients with Parkinson's disease (PD) treated with L‐Dopa/benserazide and entacapone, a peripheral catechol‐__O__‐methyltransferase (COMT) inhibitor, in a placebo‐

Intravenous boluses and continuous infus
Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease
✍ Dr. F. Stocchi; S. Ruggieri; A. Carta; J. Ryatt; N. Quinn; P. Jenner; C. D. Mars 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 641 KB

## Abstract In six patients with Parkinson's disease exhibiting severe “on‐off” phenomena, a 200‐mg intravenous bolus of either L‐DOPA or of its methyl ester were equally effective in reversing motor deficits, although the duration of action of the methyl ester was shorter. There were no marked dif